WallStreetZenWallStreetZen

NASDAQ: VERV
Verve Therapeutics Inc Stock Ownership - Who owns Verve Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Verve Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Allison DorvalChief Financial Officer2025-04-023,350$4.15
$13.90kSell
Andrew D. AshePresident Chief Operating Officer and General Counsel2025-04-022,681$4.15
$11.13kSell
Troy ListerChief Scientific Officer2025-04-022,189$4.15
$9.08kSell
Joan NickersonChief Administrative Officer2025-04-022,777$4.15
$11.52kSell
Jason PolitiChief Technical Ops. Off.2025-04-023,235$4.15
$13.43kSell
Sekar KathiresanChief Executive Officer2025-04-029,822$4.15
$40.76kSell
Allison DorvalChief Financial Officer2024-12-02555$5.64
$3.13kSell
Sekar KathiresanChief Executive Officer2024-06-2830,000$2.87
$86.10kBuy
Andrew D. AshePresident Chief Operating Officer2024-05-1476,000$6.26
$475.76kBuy

1 of 1

VERV insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when VERV insiders and whales buy or sell their stock.

VERV Shareholders

What type of owners hold Verve Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Alphabet Inc13.91%12,349,086$56.68MInstitution
Krishna Yeshwant13.70%12,168,489$55.85MInsider
Gv 2017 GP LLC11.68%10,368,489$47.59MInsider
Blackrock Inc8.48%7,525,470$34.54MInstitution
Bvf Inc7.78%6,904,050$31.69MInstitution
Gv 2019 GP LLC5.04%4,472,509$20.53MInsider
Vanguard Group Inc4.51%4,006,634$18.39MInstitution
Casdin Capital LLC4.50%3,995,571$18.34MInstitution
Millennium Management LLC4.41%3,919,131$17.99MInstitution
Schonfeld Strategic Advisors LLC4.27%3,789,379$17.39MInstitution

1 of 3

VERV vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
VERV63.38%36.62%Net BuyingNet Selling
DNA9.80%90.20%Net SellingNet Selling
MNMD48.11%51.89%Net SellingNet Selling
TRML56.98%43.02%Net Buying
PRTC0.14%0.00%
View Top Biotech Stocks

Verve Therapeutics Stock Ownership FAQ

Who owns Verve Therapeutics?

Verve Therapeutics (NASDAQ: VERV) is owned by 88.59% institutional shareholders, 51.17% Verve Therapeutics insiders, and 0.00% retail investors. Krishna Yeshwant is the largest individual Verve Therapeutics shareholder, owning 12.17M shares representing 13.70% of the company. Krishna Yeshwant's Verve Therapeutics shares are currently valued at $58.17M.

If you're new to stock investing, here's how to buy Verve Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.